NCT04625595 - Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

May 11, 2021

Study Completion Date

July 31, 2021

Conditions

Type1 Diabetes

Interventions

DRUG

350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule

Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily

DRUG

700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule

Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily

DRUG

1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule

Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily

DRUG

1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule

Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily

Trial Locations (3)

Barbara Davis Center, Aurora

Prosciento, Inc., Chula Vista

Rainier Clinical Research Center, Renton